Zenuzolac is under clinical development by Inovio Pharmaceuticals and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia. According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) Pneumonia have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zenuzolac’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zenuzolac overview
Zenuzolac (VGX-1027) is under development for the treatment of severe pneumonitis caused by Coronavirus Disease 2019 (COVID-19), inflammatory diseases and diabetic nephropathy. The drug candidate is administered through oral route. It acts by targeting pro-inflammatory responses including TNF-alpha, NF-kB and P38 MAP kinase signaling pathways.
It was also under development for the treatment of rheumatoid arthritis (RA), type 1 diabetes (T1D), Crohn's disease, uveitis and colitis.
Inovio Pharmaceuticals overview
Inovio Pharmaceuticals (Inovio) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. Its major pipeline products includes VGX-3100 for the treatment of cervical HSIL, vulvar HSIL, anal HSIL; INO-5401 for glioblastoma; and INO-3107 for recurrent respiratory papillomatosis (RRP). The company is also engaged in development programs in partnership with several companies and government bodies to develop therapeutics for infectious diseases such as HIV, Ebola, Middle East respiratory syndrome (MERS), Lassa fever and COVID-19. Inovio is headquartered in Plymouth Meeting, Pennsylvania, the US.
For a complete picture of Zenuzolac’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
